Is Shattuck Labs (NASDAQ:STTK) In A Good Position To Deliver On Growth Plans?
Evercore Initiates Shattuck Labs(STTK.US) With Buy Rating
Evercore analyst Jonathan Miller initiates coverage on $Shattuck Labs(STTK.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 25.0% and a total average return of -27.
Evercore ISI Keeps Their Buy Rating on Shattuck Labs (STTK)
Insider Buys Additional US$50k In Shattuck Labs Stock
BTIG Downgrades Shattuck Labs(STTK.US) to Hold Rating
BTIG analyst Kaveri Pohlman downgrades $Shattuck Labs(STTK.US)$ to a hold rating.According to TipRanks data, the analyst has a success rate of 23.2% and a total average return of -12.1% over the past
BTIG Sticks to Its Hold Rating for Shattuck Labs (STTK)
Shattuck Labs(STTK.US) Director Buys US$32,768.24 in Common Stock
$Shattuck Labs(STTK.US)$ Director Brous Tyler purchased 8,416 shares of common stock on Jun 27, 28, 2024 at an average price of $3.89 for a total value of $32,768.24.Source: Announcement What is state
Shattuck Labs Announces Addition to Russell 2000 and Russell 3000 Indexes
Shattuck Labs(STTK.US) Officer Buys US$50,011.2 in Common Stock
$Shattuck Labs(STTK.US)$ Officer Schreiber Taylor purchased 14,400 shares of common stock on Jun 26, 2024 at an average price of $3.473 for a total value of $50,011.2.Source: Announcement What is stat
Shattuck (STTK) Stock Started Recovering After-Hours
Shattuck Labs Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Shattuck Labs(STTK.US) With Buy Rating, Cuts Target Price to $16
H.C. Wainwright analyst Joseph Pantginis maintains $Shattuck Labs(STTK.US)$ with a buy rating, and adjusts the target price from $28 to $16.According to TipRanks data, the analyst has a success rate o
Express News | Shattuck Labs Inc : H.c. Wainwright Cuts Target Price to $16 From $28
Shattuck Labs Is Maintained at Buy by Citigroup
Citigroup Maintains Buy on Shattuck Labs, Lowers Price Target to $9
Express News | Shattuck Labs Inc : Btig Cuts to Neutral From Buy
Shattuck Labs' innovative immunotherapy has achieved positive results in frontline cancer treatment.
Shattuck Labs announced the latest mid-term data from the Phase 1b dose expansion clinical trial of its investigational therapy SL-172154.
BTIG Downgrades Shattuck Labs(STTK.US) to Hold Rating, Cuts Target Price to $5
BTIG analyst Kaveri Pohlman downgrades $Shattuck Labs(STTK.US)$ to a hold rating, and adjusts the target price from $12 to $5.According to TipRanks data, the analyst has a success rate of 25.8% and a
Shattuck Labs Is Maintained at Buy by Needham
Assessing Shattuck Labs: Insights From 6 Financial Analysts